Navigation Links
Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
Date:6/19/2009

AURORA, Ontario, June 19 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: HBP) today announced that Dr. Heman Chao, chief scientific officer at Helix BioPharma Corp., will be presenting a scientific poster describing L-DOS47 analytical method development findings at the 2009 American Association of Pharmaceutical Scientists ("AAPS") National Biotechnology Conference, which runs from June 21st to 24th at the Washington State Convention and Trade Center in Seattle, Washington.

The conference is a premier gathering of pharmaceutical and biopharmaceutical scientists addressing all areas of the manufacturing, non-clinical testing, clinical testing and regulatory treatment of established and emerging drug compounds.

The poster, entitled "Analytical Method Development for L-DOS47, a Novel Candidate for the Treatment of Lung Adenocarcinoma" provides a summary of the analytical methods which have been developed to characterize the concentration, identity, purity, enzymatic activity, and potency of lots of L-DOS47 drug substance and drug product. The work presented demonstrates that analytical methods have been successfully developed to support the manufacture, release and subsequent stability testing of GMP batches of L-DOS47 as Helix progresses towards initiating clinical testing with the product. Accompanying Dr. Chao for the poster presentation will be Dr. Juan Davagnino, associate director, biopharmaceutical development at KBI Biopharma; Helix's U.S.-based, third-party contract service provider responsible for assisting Helix in developing and executing the necessary quality control and stability testing programs for L-DOS47 drug substance and drug product lots.

A copy of the poster is available on Helix's website for download at http://www.helixbiopharma.com.

F
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
2. Helix BioPharma to Present at the BioFinance 2009 Conference
3. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
4. Helix BioPharma Announces Q2 2009 Financial Results
5. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
6. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
7. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
8. Helix BioPharma Announces Q1 2009 Financial Results
9. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
10. Helix BioPharma Corp. Announces Fiscal 2008 Results
11. Helix Biopharma Closes $11.4 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... , July 3, 2015 /PRNewswire/ ... hakea verkossa osoitteessa  http://www.openinnovationinscience.at ... Innovation in Science" -jatkokoulutusohjelmaan 22.7.2015 ... Gesellschaftin (LBG) tekemän, kansainvälisiä tutkijoita ... terveystieteiden kaksi suurinta haastetta ovat ...
(Date:7/3/2015)...  Pomerantz LLP announces that a class action lawsuit ... the "Company")(NYSE: PBYI ) and certain of its ... Court, Central District of California , ... class consisting of all persons or entities who purchased ... 2015 inclusive (the "Class Period").  This class action seeks ...
(Date:7/2/2015)... July 2, 2015 Amici Procurement ... procurement company Amici Procurement has chosen Microsoft Cloud Solution ... move to Office 365.      (Logo: http://photos.prnewswire.com/prnh/20121126/579634) ... to medium-sized companies in the bio-tech sector with a ... the purchasing cycle to help them obtain best value. ...
(Date:7/1/2015)... 2015   Decision Resources Group finds ... Otezla are its oral administration, alternative mechanism of ... surveyed rheumatologists. Otezla was the first oral therapy ... active psoriatic arthritis in the United ... includes conventional oral treatments including disease-modifying antirheumatic drugs ...
Breaking Biology Technology:Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4Biotech Procurement Company Moves to Office 365 with iomart 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3
... 2 HUYA Bioscience,International (HUYA), a rapidly ... key disease-fighting drugs sourced from China,announced today ... stage anti-arrhythmic,compound from the prestigious Shanghai Institute ... The compound, HBI-3000 or sulcardine, exhibits ...
... Cost-Effective, Time-Saving, ATLANTA, Oct. 1 ... CliniCom(TM), a revolutionary software platform,designed to assess ... CliniCom(TM), an intuitive, computer assisted intake ... health settings, gathers information,directly from patients and ...
... Center,has awarded a five-year, $120-million extension of its ... also known,as NSBRI, of Houston. Under the extension, ... biomedical research in support of a,long-term human presence ... cooperative agreement began April 1, 1997, with,a value ...
Cached Biology Technology:HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica 2HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica 3Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology 2Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology 3
(Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/30/2015)... 2015 Genisphere announced Tom ... help further develop Genisphere,s therapeutics capabilities and portfolio. Mr. ... spent much of the last 25 years in leadership ... and Johnson & Johnson. Tom started his career in ... Corporate Finance. He graduated from Dartmouth College with a ...
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical contract manufacturing ... headquartered in Springville, Utah , has announced ... corporation with locations in Santa Clara, CA ... ). This acquisition will incorporate MedConx,s manufacturing facility ... existing facility in Costa Rica , resulting ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2
... Department of Energy,s Pacific Northwest National Laboratory will present ... American Geophysical Union Fall Meeting, which runs Monday, Dec. ... Center in San Francisco. Topics to be discussed include ... grow algae for biofuel and predicting the environmental impacts ...
... that lions are rapidly and literally losing ground across ... and subsequent, massive land-use conversion. Representing the most comprehensive ... habitat to date, the report maintains that the lion ... Africa a reduction that has devastated lion populations ...
... -- December 4, 2012 -- The William R. Kenan, ... of The Scripps Research Institute, $1 million to support ... The grant represents the largest single gift to date ... Building upon seven years of Kenan Trust support, the ...
Cached Biology News:Sunshine, biofuel and the tides, oh my! 2Sunshine, biofuel and the tides, oh my! 3New study reveals lions are rapidly losing ground in Africa 2New study reveals lions are rapidly losing ground in Africa 3